EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery
EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery

Average (ratings)
No ratings
 
  Your rating

In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery.

SGLT2 inhibitors are proving to be the blockbuster drug of this decade: Sukh summarises and compares the learnings from DAPA-HF, Emperor-Reduced, and Emperor-Preserved. Next, Sukh highlights the data from SOLOIST-WHF that showed sotagliflozin to have beneficial effects on CV outcomes among patients with type 2 diabetes and HF. Additionally, they discuss how findings on finerenone (FIGARO-DKD) will shape the field. Sukh talks about the semaglutide and the STEP studies, an injectable medication that further expends cardiologist knowledge beyond their speciality. Ankur and Sukh reflect on how the advancement of this field shaped their own practices.

2021 was a busy year for cardiac surgery trials: Sukh and Ankur review the most pertinent data from the AVATAR randomised study presented at AHA 2021. Sukh interprets the outcomes and asks Ankur about his clinical experiences. Finally, they review the investigator led LAAOS III study that showed patients with atrial fibrillation undergoing cardiac surgery, left atrial appendage occlusion was superior to no occlusion.

What were the top practice informing heart failure trials of 2021? What does the latest data say on current cardiac surgery practices? How will these findings inform patient care?

Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.


Read MoreRead Less
Share
Edwards: www.edwardstavr.com

Brought to you by Edwards: www.edwardstavr.com

Read MoreRead Less
Up Next
EP 62: Bullying, Harassment and Jealousy at Workplace with Dr Srihari S Naidu
EP62 • Jan 31, 2022 • 43m 38s
In this week's Parallax, Dr Ankur Kalra is joined by Dr Srihari S Naidu, Director of Cath Labs and Hypertrophic Cardiomyopathy Center at the Westchester Medical Center and President Elect of NY ACC, for an honest conversation on a challenging topic within the cardiology community.
Read More
All Episodes
01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger
EP01 • Apr 23, 2020 • 27m 44s
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Ep 81: @Medlife Crisis and Authenticity with YouTuber & Interventionalist, Dr Rohin Francis
EP81 • Dec 05, 2022 • 44m 41s
Rohin believes that authenticity is one of the keys of his videos’ success. When asked about his journey to medicine he summarises: “I was being rebellious and ended up doing the most cliché job for an Indian possible.” He turns the table and asks Ankur what he think is behind the stereotype of the Indian cardiologist.
Rohin shares an advice that he received at the beginning of his career: “If you can deal with an average day, the exciting day will take care of itself.”
Ankur asks Rohin about Medlife Crisis and the work that goes into producing a show followed by 500K people. Rohin reiterates his passion for research and science communication. Ankur and Rohin discuss what it means to be yourself on social media and what is Rohin’s advice to our early-career listeners.
Read More
EP 80: AHA’s Scientific Sessions: Science, Innovation and Community With Dr Manesh Patel
EP80 • Nov 21, 2022 • 39m 43s
Year on year, the organisers of the Scientific Sessions aim to give platform to cardiovascular science at its best: innovative, impactful, and collaborative.
In this information-packed episode, Dr Patel takes us behind the scenes and talks about the work that goes into the curation of the programme and the considerations that shape the event. Dr Kalra asks Dr Patel about his highlights over the years and the movement and changes that he observed as vice chair and chair of the event. Dr Patel elaborates on the key late-breaking science trials in 2022. Dr Kalra and Dr Patel discuss the grading system of the award applications and share some useful information with our listeners.
Read More
Guest Episode: Exploring Art & Advancement Within Medicine
EP79 • Oct 31, 2022 • 33m
This week's Parallax is hosting a guest episode recorded for Internal Medicine & Beyond. Tune in to this new podcast from Dr Varun Aitharaju.

Exploring Art & Advancement Within Medicine - A Conversation with an Interventional Cardiologist.
Read More
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani
EP78 • Oct 10, 2022 • 46m 28s
This week’s Parallax episode is focusing on the latest science and questions surrounding one of the conundrums of cardiovascular science: Lipoprotein(a).
Dr. Ankur Kalra invites Dr Salim S Virani to help simplify the concept of Lp(a) with answering key questions about its measurement and its place in practice and prevention.
Read More
ESC 22 in Review With Dr P Parwani: 5 Trials That Will Change Your Practice
EP77 • Sep 26, 2022 • 1h 7m 31s
Back by popular demand, Dr Ankur Kalra's guest is Dr Purvi Parwani, Director of Women’s Cardiovascular Disease Clinic and Assistant Professor at Loma Linda University Medical Center, US. In this ESC 2022 edition of Parallax, Ankur asks Purvi to review her highlights of the congress. Purvi details the study design and key findings of each trial and provides her insights after attending the event in Barcelona. Ankur and Purvi discuss how each trial will inform their practice.
Read More